Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vantia LtdfiledCriticalVantia Ltd
Publication of AR116040A2publicationCriticalpatent/AR116040A2/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
La presente provee para-toluensulfonato de 4-(6-cloro-3-metil-4,10-dihidro-3H-2,3,4,9-tetraazabenzo[f]azulen-9-carbonil)-2-fluoro-bencilamida de ácido ciclopropancarboxílico, composiciones farmacéuticas que lo contienen, y su uso en terapia.This document provides 4- (6-chloro-3-methyl-4,10-dihydro-3H-2,3,4,9-tetraazabenzo [f] azulene-9-carbonyl) -2-fluoro-benzylamide para-toluenesulfonate of cyclopropanecarboxylic acid, pharmaceutical compositions containing it, and its use in therapy.
Pharmaceutical formulations of an anti cd-20 antibody; use of the formulation to treat disease or disorder that can be corrected by anti-cd20 antibody treatment.
Compounds derived from substituted piperidine; Preparation process; Pharmaceutical composition and its use to produce an antiproliferative and / or proapoptotic effect.
combination pharmaceutical compositions, patient treatment methods and use of activated potentiated form of angiotensin ii receptor 1 antibody and activated potentiated form of endothelial synthase antibody
Tamarind seed polysaccharide for use in the treatment of infectious diseases; pharmaceutical and / or anti-inflammatory dermocosmetic composition containing said polysaccharide; use of a tamarind seed polysaccharide.